As the number of effective therapies for treatment of multiple myeloma continues to increase, a greater proportion of patients are achieving deep therapeutic responses.1, 2, 3 Traditionally, serum and urine M-protein measurements by immunoelectrophoresis were sufficient to define treatment responses in 90% of cases.4 However, as more patients have deeper treatment responses, current M-protein detection methods are analytically incapable of monitoring patient deep response. Here, MYOM2 is linked to plasma cell myeloma.